Neal is the Chief Executive Officer of Pathalys Pharma, Inc. He previously served as CEO of Liquidia Technologies (NASDAQ), transforming the company from an early-stage research platform into a publicly traded biomedicines company. While at Liquidia, Neal also co-founded and served as CEO of Envisia Therapeutics (acquired), an ophthalmology therapeutics company. Prior to Liquidia, Neal worked for seven years with Johnson and Johnson, serving as President of Centocor, Inc., a global multi-billion dollar subsidiary focused on biomedicines, and President of Ortho-McNeil Neurologics, a company focused on neurological disorders. Neal started his career with Eli Lilly and Company, working for thirteen years in a variety of sales, marketing and business development roles in both the pharmaceutical and medical device divisions. Neal is the current chair of both NCBIO and the UNC Eshelman School of Pharmacy Foundation and serves on the board of Emergent BioSolutions (NYSE). He is a native of Raleigh, NC and earned his BS degree in Pharmacy and MBA, both from the University of North Carolina at Chapel Hill.